Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron
Background: Chronic diseases reduce the availability of iron for effective erythropoiesis. This review summarises clinical consequences of iron deficiency (ID) and anaemia in cancer patients, mechanisms how impaired iron homeostasis affects diagnosis and treatment of ID, and data from clinical trials evaluating i.v. iron with or without concomitant erythropoiesis-stimulating agents (ESAs).......
Blogger's Note: table includes solid tumors
Table 1.
Reported prevalence of iron deficiency in different cancer patient populations
"potential role for i.v. iron as first-line therapy for CIA?
Guidelines recommend treatment of
underlying causes of anaemia such as ID before initiation of an ESA.
However, studies examining
i.v. iron as sole anaemia treatment in cancer
patients are only just starting to emerge. Two relevant small (N
= 44 and 75 patients), controlled, randomised clinical trials have been
published. Both studies involved patients with gynaecologic
cancers receiving chemotherapy or
radiochemotherapy, and in both, i.v. iron supplementation significantly
reduced the number
of required blood transfusions [15, 16].
In one study, significantly higher Hb levels were observed in the i.v.
iron compared with the oral iron group at the end
of the study period, although mean Hb levels
included data from patients who received transfusions as well as those
who did
not [15]. The other study, comparing i.v. iron versus no anaemia treatment, achieved a lower rate in transfusions despite a higher
baseline proportion of anaemic patients in the study group [16]. Both studies missed to assess iron status parameters such as TSAT and serum ferritin; thus, the proportion of patients
with either functional or absolute ID could not be determined."
cross references:
- 15.↵
- 16.↵Concluding remarksThe high prevalence of ID and anaemia in cancer patients suggests that these complications may need more attention in clinical practice. Current guidelines for treating anaemic cancer patients recommend that ID should be considered as underlying cause of anaemia before initiating ESA treatment and acknowledge that i.v. iron supplementation is superior to oral iron. .....................Published randomised controlled trials show that i.v. iron enhances response rates to ESA therapy and may be effective in reducing ESA doses and blood transfusion requirements, even if long-term safety remains to be examined. Available early reports on the use of i.v. iron as first-line anaemia therapy suggest that some patients could benefit from i.v. iron even without concomitant ESA. However, larger randomised controlled studies with long-term follow-up are necessary to confirm long-term efficacy and safety.
- 16.↵
